Harbour Investments Inc. Acquires 2,906 Shares of Exact Sciences Corporation $EXAS

Harbour Investments Inc. raised its holdings in Exact Sciences Corporation (NASDAQ:EXASFree Report) by 14.7% during the second quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 22,729 shares of the medical research company’s stock after buying an additional 2,906 shares during the quarter. Harbour Investments Inc.’s holdings in Exact Sciences were worth $1,208,000 at the end of the most recent quarter.

Several other hedge funds also recently made changes to their positions in the company. Great Lakes Advisors LLC boosted its position in shares of Exact Sciences by 3.7% during the first quarter. Great Lakes Advisors LLC now owns 4,971 shares of the medical research company’s stock valued at $215,000 after purchasing an additional 178 shares in the last quarter. Nissay Asset Management Corp Japan ADV boosted its position in shares of Exact Sciences by 0.8% during the first quarter. Nissay Asset Management Corp Japan ADV now owns 22,432 shares of the medical research company’s stock valued at $971,000 after purchasing an additional 187 shares in the last quarter. OneDigital Investment Advisors LLC boosted its position in shares of Exact Sciences by 0.3% during the first quarter. OneDigital Investment Advisors LLC now owns 100,872 shares of the medical research company’s stock valued at $4,367,000 after purchasing an additional 270 shares in the last quarter. IFP Advisors Inc boosted its position in shares of Exact Sciences by 6.5% during the second quarter. IFP Advisors Inc now owns 4,466 shares of the medical research company’s stock valued at $237,000 after purchasing an additional 273 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in shares of Exact Sciences by 37.0% during the second quarter. Farther Finance Advisors LLC now owns 1,018 shares of the medical research company’s stock valued at $54,000 after purchasing an additional 275 shares in the last quarter. 88.82% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Exact Sciences

In other news, Director James Edward Doyle sold 2,000 shares of the business’s stock in a transaction on Thursday, October 9th. The stock was sold at an average price of $60.00, for a total value of $120,000.00. Following the completion of the transaction, the director owned 57,962 shares in the company, valued at $3,477,720. The trade was a 3.34% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.20% of the stock is owned by corporate insiders.

Exact Sciences Trading Down 0.1%

Exact Sciences stock opened at $61.23 on Friday. The company has a current ratio of 2.89, a quick ratio of 2.56 and a debt-to-equity ratio of 0.94. The business’s fifty day simple moving average is $52.24 and its two-hundred day simple moving average is $51.07. Exact Sciences Corporation has a 12 month low of $38.81 and a 12 month high of $72.83. The company has a market capitalization of $11.59 billion, a price-to-earnings ratio of -11.28, a price-to-earnings-growth ratio of 5.66 and a beta of 1.24.

Exact Sciences (NASDAQ:EXASGet Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The medical research company reported $0.22 earnings per share for the quarter, topping the consensus estimate of ($0.02) by $0.24. Exact Sciences had a negative return on equity of 1.75% and a negative net margin of 34.19%.The firm had revenue of $811.09 million during the quarter, compared to analysts’ expectations of $774.43 million. During the same quarter in the previous year, the business earned ($0.09) earnings per share. The company’s revenue was up 16.0% on a year-over-year basis. As a group, equities analysts predict that Exact Sciences Corporation will post -0.58 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on EXAS. UBS Group dropped their price target on Exact Sciences from $61.00 to $53.00 and set a “neutral” rating on the stock in a research report on Thursday, August 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Exact Sciences in a research report on Wednesday, October 8th. Craig Hallum lifted their price target on Exact Sciences from $65.00 to $85.00 and gave the company a “buy” rating in a research report on Thursday, September 11th. Cowen reissued a “buy” rating on shares of Exact Sciences in a report on Thursday, August 7th. Finally, Wells Fargo & Company set a $68.00 target price on Exact Sciences in a report on Wednesday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Exact Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $69.19.

View Our Latest Stock Analysis on Exact Sciences

About Exact Sciences

(Free Report)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.

See Also

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXASFree Report).

Institutional Ownership by Quarter for Exact Sciences (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences and related companies with MarketBeat.com's FREE daily email newsletter.